Suppression of Interferon-α Treatment Response by Host Negative Factors in Hepatitis B Virus Infection
Chronic hepatitis B virus (CHB) infection remains a major global public health issue for which there is still lacking effective curative treatment. Interferon-α (IFN-α) and its pegylated form have been approved as an anti-HBV drug with the advantage of antiviral activity and host immunity against HB...
Main Authors: | Jiayi Wang, Lingyao Du, Hong Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.784172/full |
Similar Items
-
Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C
by: Maria Helena Postal Pavan, et al. -
Protection of Ducklings from Duck Hepatitis A Virus Infection with ELPylated Duck Interferon-α
by: Yongjuan Wang, et al.
Published: (2022-03-01) -
Pegilated interferon α2а in treatment of chronic hepatitis C
by: P. O. Bogomolov, et al.
Published: (2012-09-01) -
Trained innate immunity and human adenovirus infection as a novel mechanism linked to the severe acute hepatitis of unknown origin in children during the COVID‐19 pandemic
by: Lingyao Du, et al.
Published: (2022-09-01) -
Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C
by: Yuanji Ma, et al.
Published: (2024-11-01)